In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Oral anticoagulants plus antiplatelets associated with poor outcome in atrial fibrillation

Atrial Fibrillation

Munich, Germany – 28 Aug 2018: Combined oral anticoagulant and antiplatelet therapy is associated with a worse prognosis than anticoagulation alone in newly diagnosed atrial fibrillation patients without a clear indication for antiplatelets, according to late breaking results from the GARFIELD-AF registry presented today at ESC Congress 2018. (1)

Professor Keith Fox, principal investigator, University of Edinburgh, UK, said: “These findings challenge the use of combined oral anticoagulant and antiplatelet therapy in patients with atrial fibrillation, especially those without an indication for antiplatelet therapy.”

Anticoagulants and antiplatelets are both antithrombotic drugs, meaning they prevent the formation of blood clots. Anticoagulants do this by stopping the circulation of proteins needed for clotting, while antiplatelets stop platelets sticking together.

Nearly all patients diagnosed with atrial fibrillation should be started on oral anticoagulation to prevent stroke. (2) Adding an antiplatelet increases the risk of bleeding and is not recommended unless required to prevent coronary or peripheral artery thrombosis – for example in patients who have received a stent, had a myocardial infarction, or have peripheral artery disease.

This analysis of the GARFIELD-AF registry (3) investigated whether adding an antiplatelet to oral anticoagulation therapy in those without a clear indication for an antiplatelet would provide an overall benefit or harm. Patients were excluded if they had previously been prescribed antiplatelets, which included aspirin and P2Y12 receptor inhibitors.

The study enrolled 25,815 patients with newly diagnosed atrial fibrillation from 1,317 sites in 35 countries. Of those, 3,133 patients were prescribed antiplatelet and oral anticoagulant therapy for the first time and 22,682 were prescribed oral anticoagulants alone.

Patients receiving oral anticoagulants and antiplatelets had a higher prevalence of coronary artery disease, acute coronary syndrome, and stroke. However, 1,743 (56%) patients prescribed both drugs did not have coronary artery disease or peripheral artery disease.

Professor Fox said: “More than half of patients prescribed both drugs did not have coronary artery disease or peripheral artery disease, suggesting that they did not have a clear indication for antiplatelet therapy.”

Patients were followed-up for a minimum of 12 months. Compared to oral anticoagulation alone, combined treatment with oral anticoagulation and antiplatelet therapy was independently associated with increased risks of major bleeding (hazard ratio [HR] 1.45, 95% confidence interval [CI]  0.94–2.23), all-cause death (HR 1.31, 95% CI 1.05–1.62), and stroke (HR 1.60, 95% CI 1.08–2.35).

Associations between treatment type and outcomes were then examined in patients with an indication for antiplatelet therapy (with coronary artery disease or peripheral artery disease) and those without (no coronary artery disease or peripheral artery disease). Compared to oral anticoagulation alone, combined treatment was independently associated with increased risks of all-cause death (HR 1.37, 95% CI 1.02–1.85) and stroke (HR 1.65, 95% CI 1.02–2.65) in patients without an indication for antiplatelets, but was not harmful in those with an indication.

Professor Fox said: “Combined oral anticoagulant and antiplatelet therapy was harmful in patients without an indication for antiplatelets. In those with an indication, it was not harmful but there did not appear to be any benefit. The results question the use of combined treatment in any patient with atrial fibrillation, but particularly in those without an indication for antiplatelets.”

Professor Fox noted that the findings only apply to full dose anticoagulation. He added: “Patients with atrial fibrillation yet neither coronary artery disease nor other forms of atherosclerosis receiving both medications should consult their doctor.”


Notes to editor

SOURCES OF FUNDING: The GARFIELD-AF registry is funded by an unrestricted research grant from Bayer AG, Berlin, Germany.

DISCLOSURES: Professor Fox’s disclosures are grants from Bayer/Janssen and AstraZeneca and consulting for Bayer/Janssen, Sanofi/Regeneron, Verseon.


(1) "GARFIELD-AF prospective registry - Adverse one-year outcomes for patients newly treated with oral anticoagulants plus antiplatelet therapy after a diagnosis of atrial fibrillation” will be presented during the session Late Breaking Registry Results 2 on Tuesday 28 August from 14:30 to 15:45 at the Centre Stage – The Hub.

(2) Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962. doi:10.1093/eurheartj/ehw210.

(3) The Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) registry is the largest prospective global registry of patients with AF (including 57,262 in total and 52,000 patients recruited prospectively between 2010 and 2016). Patients with newly diagnosed non-valvular AF and at least one risk factor for stroke were enrolled from over 1,000 centres in 35 countries worldwide, including from the Americas, Europe, Africa and Asia-Pacific. Follow-up data was captured for a minimum of two and up to eight years after diagnosis to create a comprehensive database of treatment decisions and outcomes in everyday clinical practice.

ESC Press Office
For press enquiries, independent comment, please contact the ESC Press Office at

To access congress scientific resources visit ESC Congress 365.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2018

ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2018 takes place 25 to 29 August at the Messe München in Munich, Germany. Explore the scientific programme.


This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2018. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.